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Abstract
Background: In low tuberculosis (TB) incidence countries TB affects mostly immigrants in the
productive age group. Little empirical information is available about direct and indirect TB-related
costs that patients face in these high-income countries. We assessed the direct and indirect costs
of immigrants with TB in the Netherlands.
Methods: A cross-sectional survey at 14 municipal health services and 2 specialized TB hospitals
was conducted. Interviews were administered to first or second generation immigrants, 18 years
or older, with pulmonary or extrapulmonary TB, who were on treatment for 1–6 months. Out of
pocket expenditures and time loss, related to TB, was assessed for different phases of the current
TB illness.
Results: In total 60 patients were interviewed. Average direct costs spent by households with a
TB patient amounted €353. Most costs were spent when being hospitalized. Time loss (mean 81
days) was mainly due to hospitalization (19 days) and additional work days lost (60 days), and
corresponded with a cost estimation of €2603.
Conclusion: Even in a country with a good health insurance system that covers medication and
consultation costs, patients do have substantial extra expenditures. Furthermore, our patients lost
on average 2.7 months of productive days. TB patients are economically vulnerable.
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Background
Tuberculosis (TB) affects people within the most produc-
tive age group and the resultant economic costs for society
are high [1,2]. Previous studies on the economic aspects of
TB control have focused on health system costs for inter-
ventions like screening, or on evaluation of these inter-
ventions [3-10]. There is little information about the TB
related costs incurred by TB patients and their households
throughout the entire illness, including the pre-diagnostic
phase. The only studies assessing patient and household
costs have been conducted in high TB prevalence and low-
income countries [6,11-16], but are lacking for low-prev-
alence and high-income countries. Health policy makers
need this information to assess the overall economic
impact of TB. Even though in most countries diagnostic
and treatment services for TB control are offered free of
charge, TB patients do have out of pocket expenditures
[11,12].
As in many other low-incidence countries, in the Nether-
lands, immigrants and refugees contribute to a high TB
case load, compared to native inhabitants [3,17,18]. In
2007, among the 960 registered TB patients in the Nether-
lands 592 (61%) were foreign-born. Enrolment in a pri-
vate health insurance is compulsory for all inhabitants in
the Netherlands. Beside the mandatory basic health insur-
ance (approximately €95 per month), people can addi-
tionally choose for a more extended insurance with a
higher coverage. Moreover, individuals with a yearly gross
income below €26071 qualify for a health care allowance
of maximum €36 per month. In 2007, the basic health
insurance covered all costs of TB medication, most diag-
nostic tests, doctors' consultation and hospitalisation, but
not costs related to travel and food supplements etc. Since
immigrants are often faced with lower annual incomes
than the non-migrant population, TB related expenditures
not covered by the health insurance might be dispropor-
tionately higher for immigrants than for non-migrant
patients.
In this study we describe the direct and indirect costs of TB
among immigrants with TB disease in the Netherlands.
Methods
Study design and population
Between April 2007 and October 2007 we conducted a
cross-sectional survey at the 14 municipal health services
(MHSs) and the two specialized TB hospitals that volun-
teered to participate in the Netherlands. They were
selected based on the largest number of patients, being
usually from larger cities. This study was part of a multi-
centre international study on cost-effectiveness of world-
wide interventions, coordinated by McGill University in
Montreal, Canada. In this paper we present the data col-
lected in the Netherlands.
We included tuberculosis patients who were a first or sec-
ond generation immigrants, who were on anti-TB treat-
ment and aged 18 years or older. First generation
immigrants were those individuals born in a foreign
country and who were living in the Netherlands at the
time of diagnosis of active TB. Second generation immi-
grants were those individuals who were born in the Neth-
erlands, but who had at least one parent that was born
abroad.
Data collection
Patients who fulfilled the inclusion criteria were invited to
participate in the study by the nurse from the MHS or spe-
cialized TB hospital. One of two trained interviewers
explained the study, obtained informed consent and per-
formed an in-depth face-to-face interview. A structured
questionnaire was used, developed by McGill University
(Montreal, Canada), that had been successfully used in
previous studies [6,10,11], and was adapted to the Dutch
setting. Patients who were unable to speak Dutch or Eng-
lish were helped by family members or friends who could
speak one of these two languages. If necessary a translator
assisted by telephone. Interviews were done in a private
room, without the presence of any medical staff in order
to guarantee the patients' privacy.
Medical information from all TB patients in the Nether-
lands is registered in the Netherlands Tuberculosis Regis-
ter (NTR). The NTR-committee and all participating MHSs
gave permission to extract anonymous medical data from
this register for the study population. To verify if our study
population was comparable to all TB patients we com-
pared our study population with all TB patients (who ful-
filled the study inclusion criteria) who were diagnosed in
2005. Since complete national data were at the time of the
study only available for 2005 we assumed that TB cases
notified in the NTR in 2005 were comparable to those of
2007. No ethical approval was needed for this study from
the Central Committee on Research Involving Human
Subjects (CCMO) as our questionnaire did not involve
any intrusive questions.
Costs assessed
Information about costs was ascertained for different peri-
ods starting from the moment of onset of symptoms up to
the completion of treatment. Direct costs and time loss
during the different periods were asked per visit. Since
patients were still under treatment at the moment of the
interview, we assumed that the length of their treatment
would be comparable with the average treatment length
of immigrant patients in 2005; which was 6.4 months for
the whole treatment. Patients who received directly
observed therapy (DOT) received their medication 3 to 5
times per week at the MHS. The duration of DOT was on
average 5.0 months in 2005 according to the Dutch sur-BMC Public Health 2009, 9:283 http://www.biomedcentral.com/1471-2458/9/283
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veillance data. All costs were extrapolated for the entire
treatment period.
Direct costs
Direct patient costs included all out of pocket expendi-
tures of patients that were attributable to their illness [19].
Direct costs included the costs of transportation to health
facilities, costs of extra food (bought during waiting time
at the health facility), extra expenditures related to hospi-
talization (which were not covered by the health insur-
ance) or over the counter medication (such as vitamin
B6). These costs were assessed both for the patient as well
as for their household members when they had extra
expenditures due to the illness of the patient.
Indirect costs
Indirect patient costs refer to the costs associated with
time lost by the patient. This loss of time included visits to
the health facilities and hospitalization as well as other
time lost due to the inability to work as a result of the ill-
ness [19]. Time loss was only collected for the patients
themselves. In order to quantify the magnitude of time
loss, the number of days lost was multiplied by the esti-
mated income of the patients. Because of the sensitivity of
the question, we did not ask the participants their exact
income, but asked them to indicate which of 4 categories
their income corresponded to. To quantify the indirect
costs, the average time loss, in days, was multiplied by the
estimated average income of the study population.
Data and statistical analysis
Questionnaires were double entered by two different per-
sons into a standardized database. Data were analysed
with SPSS 14.0. Costs and time loss were compared
between patients with pulmonary tuberculosis (PTB) and
patients with extrapulmonary tuberculosis (ETB). Patients
with both PTB and ETB were classified as PTB. Odds ratio's
(OR) for being included in our study compared to all
immigrant patient (regardless of their inclusion on our
study) were determined by logistic regression analysis, to
determine the representativeness of the patients included
in our study for all immigrant patients in 2005. P-values
were calculated by chi-square test, independent t-test or
non-parametric tests as appropriate. While data on costs
and time loss was not normally distributed, we reported
mean values to allow comparison with other published
cost estimates. In our tables also median values are given.
Results
Patient characteristics
During the study period, 60 patients fulfilled the inclu-
sion criteria and consented to participate. In general, our
study population included more males (63%) than
females (37%). The majority of the patients included in
the study were 25 to 44 years old and most patients were
first generation immigrants from Africa or Asia (Table 1).
Compared to all immigrant patients diagnosed in the
Netherlands in 2005, our study population was slightly
younger and included significantly fewer persons with
impaired immunity (i.e. patients with HIV, diabetes,
malignancy, an organ transplantation, renal insufficiency
or other causes of immune suppression or who used TNF-
α inhibitors). None of the four interviewed patients with
an impaired immunity was known to be HIV positive.
Out of 60 patients, 31 (52%) had PTB, 23 had (38%) ETB
and 6 (10%) suffered from both PTB and ETB. We did not
observe any significant differences between characteristics
of the interviewed patients with PTB and ETB, but ETB
patients tended to be older than PTB patients (Table 2).
Out of 60 participants, 34 (57%) were unemployed at the
time of the interview. Nine (26%) of the 34 unemployed
patients were asylum seekers, who are not allowed to have
a paid job during their entrance procedure. Eight other
patients (13%) stated that their unemployment was due
to their TB illness. A lot of the patients (48%) were living
alone in a household. Forty three percent of the immi-
grants with TB reported that their net household income
before diagnosis was less than €1000 per month. Post-
diagnosis this percentage increased slightly to 50%. Six
patients reported a reduction of their income, while 3
reported an increase since their diagnosis. Except for 2
patients, 58 (97%) had a health insurance.
Direct patient costs
Direct costs of immigrants during the entire TB illness
averaged  €353 (median €190) (Table 3). Almost all
patients (58/60) had some direct costs during their illness.
Expenditures of patients varied widely and total direct
costs of patients ranged from €0 to €3961. Most patients
had out of pocket expenditures during the follow-up visits
and the diagnostic period. Costs during the pre-diagnostic
period were slightly higher for patients with ETB (mean
€10, sd 18.8) compared to patients with PTB (mean €3,
sd 7.4, t-test p-value = 0.04). No differences in costs dur-
ing the other periods were observed for patients with dif-
ferent types of tuberculosis. Patient delay, defined as the
period between first symptoms and first contact with a
health care provider, did not differ between PTB patients
(mean 2.5 months, sd 6.9) and ETB patients (mean 3.0
months, sd 4.7, p = 0.79). Most costs were incurred if
patients were hospitalized. While 28 (47%) patients had
been hospitalized before, during or after their TB diagno-
sis; mean costs during hospitalization were €105 on aver-
age. During hospitalization most costs were spent on food
and other items such as the use of a TV or telephone. Addi-
tional costs consisted mainly of additional vitamins,
energy drinks and food supplements. One patientBMC Public Health 2009, 9:283 http://www.biomedcentral.com/1471-2458/9/283
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reported to have extra high rent costs due to TB, which
explains the maximum of €2400. Although in general
costs for laboratory tests, consultation and most medica-
tion are covered by the health insurance, some patients
reported that they had incurred costs on these items. In
general, direct costs were spent on additional food supple-
ments, travel to visits the health facilities and food that
was bought during waiting times (Figure 1).
Indirect costs
On average patients lost 81 days of normal productivity
due to their TB illness (median 60 days) (Table 3). All
patients had time loss (ranging from 0.5–637 days),
mainly due to travel and consultation time at different
health care facilities. ETB patients had on average signifi-
cantly more time loss during their pre-diagnostic period
than PTB patients (mean = 0.24 vs. 0.07 days respectively,
Table 1: Comparison between the interviewed immigrants in the study and all immigrants with tuberculosis diagnosed in 2005
Immigrant TB patients in 2005, N (%)* Study population, N (%)* P-value Chi-square
Total 762 (100) 60 (100)
Sex 0.49
Male 448 (59) 38 (63)
Female 314 (41) 22 (37)
Age (yr) 0.08
18–24 150 (20) 18 (30)
25–44 386 (51) 33 (55)
45–64 154 (20) 8 (13)
≥ 65 71 (9) 1 (2)
Unknown 1 (0) 0 (0)
Generation 0.43
First generation immigrant 718 (94) 58 (97)
Second generation immigrant 44 (6) 2 (3)
Region of origin 0.44
Europe 92 (12) 3 (5)
America (Central and South) 72 (9) 6 (10)
America (North) 1 (0) 0 (0)
Asia 249 (33) 18 (30)
Africa 338 (44) 33 (55)
Unknown 10 (1) 0 (0)
Localisation of TB 0.69
Pulmonary 357 (47) 31 (52)
Extrapulmonary 305 (40) 23 (38)
Pulmonary and extrapulmonary 100 (13) 6 (10)
Culture result 0.83
Positive 531 (70) 44 (73)
Negative 91 (12) 6 (10)
Not done/unknown 140 (18) 10 (17)
Previously diagnosed with TB 0.13
No 611 (80) 54 (90)
Yes 46 (6) 3 (5)
Unknown 105 (14) 3 (5)
Treatment regime < 0.01
Standard (4HRZ(E)/2HR(E)) 542 (71) 43 (72)
Other 220 (29) 9 (15)
Unknown 0 (0) 8 (13)
Impaired immunity < 0.01
No 282 (37) 40 (67)
Yes 140 (18) 4 (7)
Missing 340 (45) 16 (27)
Hospitalization 
(during TB treatment for at least 7 days)
0.16
No 438 (58) 29 (48)
Yes 232 (30) 19 (32) ‡
Unknown 92 (12) 12 (20)
Definition of abbreviations: H = isoniazid; R = rifampin; Z = pyrazinamid; E = ethambutol;
* Column percentages are given
‡ This number differs from that in Table 2 because a different definition for hospitalization is used in the NTR-database.BMC Public Health 2009, 9:283 http://www.biomedcentral.com/1471-2458/9/283
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Table 2: Socio-economic characteristics of immigrants with pulmonary tuberculosis compared to immigrants with extrapulmonary 
tuberculosis
All TB cases, N (%)* Pulmonary TB cases, N (%)*‡ Extrapulmonary TB cases, N (%)* p-value†
Total 60 37 23
Sex
Male 38 (63) 24 (65) 14 (61) 0.76
Female 22 (37) 13 (35) 9 (39)
Age (yr)
18–24 18 (30) 13 (34) 5 (23) 0.06
25–44 33 (55) 23 (61) 10 (46)
45–64 8 (13) 2 (5) 6 (27)
≥ 65 1 (2) 0 (0) 1 (5)
Region of origin
Europe 3 (5) 3 (8) 0 (0) 0.25
America (Central and South) 6 (10) 2 (5) 4 (18)
Asia 18 (30) 12 (32) 6 (27)
Africa 33 (55) 21 (55) 12 (54)
Immigration status
Landed immigrant 33 (55) 15 (41) 18 (79) 0.12
Immigrant applicant (asylum seeker) 12 (20) 10 (27) 2 (9)
Illegal immigrant 4 (7) 3 (8) 1 (4)
Accepted refugee 3 (5) 2 (5) 1 (4)
Second generation immigrant 2 (3) 2 (5) 0
Student 6 (10) 5 (14) 1 (4)
Level of education
No education 6 (10) 5 (14) 1 (5) 0.53
Primary school 11 (18) 6 (15) 5 (22)
Some high school (not completed) 10 (17) 5 (14) 5 (22)
High school 18 (30) 10 (27) 8 (35)
Above high school 15 (25) 11 (30) 4 (17)
Employment status
Employed or student 26 (43) 16 (43) 10 (43) 0.99
Unemployed 34 (57) 21 (57) 13 (57)
Unemployment due to TB 
(n = 34)
Yes 8 (24) 5 (24) 3 (23) 0.96
No 26 (76) 16 (76) 10 (77)
Pre-diagnostic period;
Monthly household income 
(after tax rebate)
< €100 4 (7) 4 (11) 0 0.27
€100 – €499 10 (17) 6 (16) 4 (17)
€500 – €999 12 (20) 5 (14) 7 (30)
≥ €1000 33 (55) 21 (57) 12 (52)
Unknown 1 (2) 1 (3) 0 (0)
Post-diagnostic period;
Monthly household income 
(after tax rebate)
< €100 2 (3) 2 (5) 0 0.82
€100 – €499 14 (23) 9 (24) 5 (22)
€500 – €999 14 (23) 8 (22) 6 (26)
≥ €1000 28 (47) 17 (46) 11 (48)
Unknown 2 (3) 1 (3) 1 (4)
Difference in income after 
diagnosis of TB
Yes, income increased 3 (5) 2 (5) 1 (4) 0.98
Yes, income decreased 6 (10) 4 (11) 2 (9)
No, no change in income 49 (82) 30 (81) 19 (83)
Unknown 2 (3) 1 (3) 1 (4)
* Column percentages are given
† P-values are calculated with the Chi-square test
‡ 6 patients with PTB and ETB, were classified as PTB.BMC Public Health 2009, 9:283 http://www.biomedcentral.com/1471-2458/9/283
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t-test p-value = 0.01). There was no difference between the
time loss during other phases of the disease between ETB
and PTB patients. The inability to work accounted for
most time loss per patient and was on average 60.5 days.
Hospitalizations led to an additional 18.6 days of time
loss and visits to health facilities accounted for 1.6 days.
The Statistics Netherlands (CBS) estimated the average
national disposable yearly income per household (after
tax rebate and reduction of social insurance and health
insurance) at €29,400 in the Netherlands in 2005 [20].
Since half of the patients in our study reported their
income to be less than €1000 per month, we decided that
a yearly household income of €12,000 (12*€1000)
would be a more appropriate estimate of the average
income of the participants in our study. To quantify the
indirect costs, the average time loss, in days, was multi-
plied by €32.25 (€1000/31; making no difference
between time loss during working days and weekend
days). Consequently, the mean indirect costs corre-
sponded with €2603 per patient.
Discussion
This study demonstrates the economic burden that immi-
grant TB patients in the Netherlands face during their TB
illness. We show that, even in a high income country
where most medical costs are covered by the mandatory
health insurance, immigrants with tuberculosis do have
extra out of pocket expenditures. Furthermore, immigrant
patients lost 81 productive days due to their illness. Costs
and time loss during the pre-diagnostic period were
slightly higher for patients with ETB compared to those
with PTB, which is possibly due to the added investiga-
tions needed to diagnose extrapulmonary tuberculosis
and exclude other pathology. Our study confirms that TB
patients are from vulnerable groups, having a high unem-
ployment rate both before their disease and even higher
during disease, and a lower average income than the gen-
eral population.
Out of pocket expenditures were comparable with 3%
(€353/€12000) of the average annual income of the
patients. These costs may be a considerable part of their
disposable income after the payment of all monthly fixed
costs such as rent, marginal costs (such as electricity and
water) and insurances. Moreover, these costs are all faced
during the time of TB disease and thus spend in a period
of around 6 months. A quarter of the interviewed TB
patients were asylum seekers, who often have even less
money to spend. Some authors have concluded that a cost
burden greater than 10% will be catastrophic for the
household [15,21]. It is debatable if this percentage can be
applied to both low and high income countries. The
amount of extra costs spend will depend on the available
income. For example, quite a number of patients reported
to spend extra money on food supplements. It can be
Type of direct costs incurred by immigrants with pulmonary or extrapulmonary tuberculosis (mean costs in euro's) during the  whole TB illness period Figure 1
Type of direct costs incurred by immigrants with pulmonary or extrapulmonary tuberculosis (mean costs in 
euro's) during the whole TB illness period. Definition of abbreviations: PTB = pulmonary tuberculosis; ETB = extrapul-
monary tuberculosis.
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questioned whether patients with little income will (or
need to) spend costs on these additional items, when they
can't pay them. Furthermore, coping strategies may have
resulted in differences in expenditures between patients,
but we did not assess how patients handled these extra
expenditures.
Opposed to our study, earlier studies on direct and indi-
rect costs due to TB were done in low-income countries.
While the total direct and indirect costs of our study pop-
ulation accounted for approximately 25% of their annual
income (€353+€2956/€12000*100%), the total costs
accounted for a considerable higher percentage in these
low-income countries [6,11,14,15]. For example, a survey
in Haiti estimated out of pocket expenses and lost income
due to TB illness to be 76% of the average per capita
income of Haitians, while a study from India showed that
TB related costs accounted for 40% of the household
income during TB illness [6,14]. The differences between
these studies and ours may be explained by different
social background, insurance system and a higher income
per inhabitant in our high-income country.
Although time loss had not affected the income of all
interviewed tuberculosis patients we did express the loss
of time in costs. The height of the indirect costs may there-
fore be an overestimation of the costs faced by the individ-
ual patient, since these costs are mostly carried by the
society. In the Netherlands, the social security system pro-
vides a benefit to all inhabitants who are jobless. Further-
more, individuals who have a job and become ill, will
mostly receive their regular income. However, 57% of the
interviewed immigrant patients was jobless and a quarter
of them attributed their unemployment to their tubercu-
losis illness. An additional ten percent of the employed
patients reported that their household income decreased
due to their TB illness. The unemployment rate among TB
patients even before their disease is higher than the
national unemployment rate among non-western immi-
grants living in the Netherlands (16%). This in turn is
much higher than that among the autochthonous Dutch
population (4%). Consequently, their estimated income
levels differ. Although we studied the TB related costs only
among immigrant patients, it can be expected that these
costs will not be much different for other TB patients,
since most expenditures were spent on travel and food
related items. However, when expressed as a percentage of
the income, these TB related expenditures will be a smaller
proportion of the income among the autochthonous TB
patients.
Our study had some limitations. First of all our study pop-
ulation, a convenience sample of TB patients of the partic-
ipating centres, was not completely representative for all
Table 3: Mean direct costs and time loss of immigrants with tuberculosis during different periods of their illness (n = 60)
Direct costs (euro's)
Patients reporting costs during this period All patients (n = 60)
N (%)* Mean costs (min-max)† Mean costs † Median costs (IQR)
Pre-diagnostic period 23 (38) €15 (€1–€72) €6 0 (0–4)
Diagnostic period 36 (60) €27 (€1–€190) €16 5 (0–16)
Follow-up visits 49 (82) €49 (€5–€195) €40 27 (10–60)
DOT visits 13 (22) €72 (€3–€417) €16 0 (0–0)
Hospitalization 21 (35) €301 (€2–€3960) €105 0 (0–51)
Additional costs 39 (65) €263 (€4–€2400) €171 64 (0–251)
TOTAL 58 (97) €365 (€3–€3961) €353 190 (74–399)
Time loss (days)
Patients reporting time loss during this period All patients (n = 60)
N (%)* Mean time loss, days (min-max) Mean time loss Median time loss (IQR)
Pre-diagnostic period 41 (68) 0.2 (0.0–1.8) 0.1 0.1 (0–0.2)
Diagnostic period 42 (70) 0.3 (0.0–1.2) 0.2 0.2 (0–0.4)
Follow-up visits 60 (100) 0.6 (0.18–2.0) 0.6 0.4 (0.3–0.8)
DOT visits 31 (52) 1.3 (0.2–6.6) 0.7 0.1 (0–0.7)
Hospitalization 28 (47) 39.9 (1.0–180.0) 18.6 0 (0–21.0)
Other workdays lost 39 (65) 93.0 (21.0–600.0) 60.5 31.0 (0–90.0)
TOTAL 60 (100) 80.7 (0.5–637.2) 80.7 59.7 (4.6–121.5)
Definition of abbreviations: IQR = inter-quarter range; DOT = directly observed therapy
* Column percentages are given
† Costs are rounded to the nearest integer.BMC Public Health 2009, 9:283 http://www.biomedcentral.com/1471-2458/9/283
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immigrant TB patients. We included younger patients and
fewer patients with an impaired immunity. Both factors
may have led to an underestimation of the cost estimates,
since older patients and those who are immunocompro-
mised may have atypical presentations of TB, delayed
diagnosis and more complex treatment needing more
medical attention during follow-up. Secondly, many of
the interviewed immigrants were unable to speak Dutch
or English. This made it sometimes difficult to obtain reli-
able information, but on the basis of a face-to-face inter-
view and with the aid of a translator the interviewers were
still able to obtain detailed information about the patient
costs. Face-to-face interviews are a good method to obtain
detailed information from the past and diminish recall
bias [22].
Lastly, we did not ask for the exact income details. In other
studies the Gross National Product (GNP) and data from
surveys by National Statistics Office were used [6,12]. The
average income we used in this study may be underesti-
mated since we did not know the maximum income in the
highest income category. If so, this will have resulted in an
underestimation of the indirect costs, and have led to an
overestimation of the relative direct costs expressed as a
percentage of the average income.
Conclusion
In conclusion, this study showed that immigrants with TB
are economically burdened in the Netherlands. Even in a
country with a good health insurance system that covers
medication and consultation costs, patients do have sub-
stantial extra expenditures. TB patients are economically
vulnerable.
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